273 results on '"Liao, Wei-Yu"'
Search Results
2. Lung adenocarcinoma with EGFR L858R-K860I and L858R-L861F doublet mutations from which the L858R mutation is undetectable through the cobas EGFR mutation test v2
3. Hope and its relationship with treatment/ physical related factors in lung cancer patients receiving immunotherapy
4. Upfront liquid next-generation sequencing in treatment-naïve advanced non-small cell lung cancer patients: A prospective randomised study in the Taiwanese health system
5. Effect of NdCoGa alloy addition to waste wind turbine magnets to enhance the characteristics of recycled sintered NdFeB permanent magnets
6. Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy
7. Comprehensive Genomic Analysis of Patients With Non–Small-Cell Lung Cancer Using Blood-Based Circulating Tumor DNA Assay: Findings From the BFAST Database of a Single Center in Taiwan
8. Tissue or liquid rebiopsy? A prospective study for simultaneous tissue and liquid NGS after first‐line EGFR inhibitor resistance in lung cancer
9. The association of EGFR amplification with aberrant exon 20 insertion report using the cobas EGFR Mutation Test v2.
10. Effects of Early Short-Course Corticosteroids on Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
11. Exon 16–Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M–Positive Non–Small Cell Lung Cancer
12. Effects of Early Short-Course Corticosteroids on Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors
13. Oral uracil–tegafur compared with intravenous chemotherapy as adjuvant therapy for resected early‐stage non‐small cell lung cancer patients
14. Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation–Positive Advanced NSCLC: Findings From a Global Named Patient Use Program
15. Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non–Small-cell Lung Cancer Patients
16. Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
17. Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery
18. Abstract 6702: The clinical characteristics and outcomes of NSCLC patients with genomic alterations detected by blood-based NGS ctDNA assay
19. A 3D culture system for evaluating the combined effects of cisplatin and anti-fibrotic drugs on the growth and invasion of lung cancer cells co-cultured with fibroblasts
20. Psychological distress and coping strategies among women with incurable lung cancer: a qualitative study
21. Mesenchymal Stem Cell Transplantation Increases Antioxidant Protein Expression and Ameliorates GP91/ROS/Inflammasome Signals in Diabetic Cardiomyopathy
22. GM2-Activator Protein: A New Biomarker for Lung Cancer
23. Paracrine IGF-1 Activates SOD2 Expression and Regulates ROS/p53 Axis in the Treatment of Cardiac Damage in D-Galactose-Induced Aging Rats after Receiving Mesenchymal Stem Cells
24. Comparative effects of oral uracil–tegafur versus intravenous chemotherapy as adjuvant therapy for resected early-stage NSCLC patients: Taiwan cancer registry cohort study
25. The unmet supportive care needs—what advanced lung cancer patients’ caregivers need and related factors
26. Adipose-Derived Stem Cells Preincubated with Green Tea EGCG Enhance Pancreatic Tissue Regeneration in Rats with Type 1 Diabetes through ROS/Sirt1 Signaling Regulation
27. Neoadjuvant Chemotherapy With Docetaxel-Cisplatin in Patients With Stage III N2 Non–Small-Cell Lung Cancer
28. Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib
29. Real-world treatment patterns and outcomes among patients with advanced non-small-cell lung cancer with spindle cell and/or giant cell carcinoma
30. Impact of PD-L1 Expression and Tumor Microenvironments on Osimertinib Efficacy in Pretreated Non-Small-Cell Lung Cancer Harboring an Acquired EGFRT790M Mutation
31. EGFR mutation and lobar location of lung adenocarcinoma
32. Monitoring levels of vimentin-positive circulating cancer stem cells and tumor cells in patients with advanced EGFR-mutated non-small cell lung cancer
33. Discordant HER2 Exon 20 Mutation Status Determines a Differential Sensitivity to Afatinib
34. Heparin co-factor II enhances cell motility and promotes metastasis in non-small cell lung cancer
35. sj-pdf-1-tam-10.1177_17588359211018022 – Supplemental material for The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 study
36. Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan
37. Symptoms, psychological distress, and supportive care needs in lung cancer patients
38. Quality of Life and Related Factors in Patients With Newly Diagnosed Advanced Lung Cancer: A Longitudinal Study
39. Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC
40. The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 study
41. Anxiety, depression and related factors in family caregivers of newly diagnosed lung cancer patients before first treatment
42. Endobronchial Ultrasound-Guided Transbronchial Biopsy of Peripheral Pulmonary Lesions: How Many Specimens Are Necessary?
43. Genetic Polymorphism of XRCC1 Arg399Gln Is Associated With Survival in Non–Small-Cell Lung Cancer Patients Treated With Gemcitabine/Platinum
44. Autophagy in fibroblasts induced by cigarette smoke extract promotes invasion in lung cancer cells
45. Tubulointerstitial nephritis associated with erlotinib therapy for lung cancer
46. Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
47. Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
48. Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients
49. TREM-1 Expression in Tumor-associated Macrophages and Clinical Outcome in Lung Cancer
50. Autocrine and Paracrine Regulation of Interleukin-8 Expression in Lung Cancer Cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.